Clinical Lung Cancer

Skip to Main Content

You have requested a feature that requires you to Log In

Email/Username

Password

Show

Forgot password?

Remember me

Don’t have an account?

Create a Free Account

If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password

Email*

If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password

Cancel

Submit Article
Log in
Register
Log in
- Submit Article
- Log in
Subscribe
Claim

Skip menu

Articles
- Latest
- Popular Articles
  
  Current Trial Report
  Open Access
  Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial
  Heymach et al.
  Review Article
  Open Access
  Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications
  Cho et al.
  Case Report
  Brief Report: Predictive value of PD-L1 Expression in non–Small-Cell Lung Cancer - Should we Set the Bar Higher for Monotherapy?
  Nikolic et al.
- Latest Articles
  Original Study
  Alternating therapy with osimertinib and afatinib blockades EGFR secondary mutation in EGFR-mutant lung cancer: A single-arm phase 2 trial
  Yonesaka et al.
  Review Article
  Lung cancer in patients with Lynch Syndrome: Association or Coincidence?
  Majeed et al.
  Original Study
  Chemoimmunotherapy as The First-Line Treatment for Patients with Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status of 2 or 3
  Agarwal et al.
Publish
- For Authors
About
- Journal Information
- Companion Journals
- Access
Contact
- Contact
- Follow Us
  - New Content Alerts
  - Twitter
    External Link

Advanced search

Please enter a term before submitting your search.

Ok

You have requested a feature that requires you to Log In

Email/Username

Password

Show

Forgot password?

Remember me

Don’t have an account?

Create a Free Account

Home
Articles & Issues
Articles In Press
Current Issue
List of Issues
Supplements
For Authors
About Open Access
Author Information
Permissions
Researcher Academy
Submit Manuscript
Journal Info
About Open Access
About the Journal
Abstracting/Indexing
Activate Online Access
Career Opportunities
Contact Information
Editorial Board
Advertising
New Content Alerts
Pricing
Reprints
Subscribe
Related Journals
Clinical Colorectal Cancer
Clinical Genitourinary Cancer
Clinical Breast Cancer
Clinical Lymphoma Myeloma Leukemia Cancer
More Periodicals
Find a Periodical
Go to Product Catalog
Qualified Recipients
Follow Us
Twitter

The content on this site is intended for healthcare professionals.

We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.

Privacy Policy
Terms and Conditions
Accessibility
Help & Contact

Popular Articles

Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial

Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications

Brief Report: Predictive value of PD-L1 Expression in non–Small-Cell Lung Cancer - Should we Set the Bar Higher for Monotherapy?

Alternating therapy with osimertinib and afatinib blockades EGFR secondary mutation in EGFR-mutant lung cancer: A single-arm phase 2 trial

Lung cancer in patients with Lynch Syndrome: Association or Coincidence?

Chemoimmunotherapy as The First-Line Treatment for Patients with Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status of 2 or 3

You have requested a feature that requires you to Log In

Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial